Literature DB >> 11997410

Improvements in total mortality and lipid levels after acute myocardial infarction in an English health district (1995-1999).

J Harrop1, R Donnelly, A Rowbottom, M Holt, A R Scott.   

Abstract

OBJECTIVES: To quantify changes in 30 day and one year mortality among patients with acute myocardial infarction in southern Derbyshire (population 560 000) in each of five consecutive years (1995-1999) before the publication of the National Service Framework for coronary heart disease, and to assess the proportion of one year survivors in whom serum lipids were measured and were below target values.
DESIGN: All hospital admissions coded on the patient administration system (PAS) as "AMI" (ICD codes I-21, I-22, and I-23) and with a creatine kinase measurement in the pathology database were identified over a five year period (n = 4912). All deaths in the district are automatically notified to the PAS. Total mortality after acute myocardial infarction (30 days and one year) and lipid levels were analysed by year of admission, age group (35-74 years v > or = 75 years), and sex using unconditional logistic regression analysis.
SETTING: An acute hospitals trust and pathology laboratory, as sole service providers for a catchment population of 560 000.
RESULTS: The number of admissions for acute myocardial infarction was similar in each of the five years (n = 4912, 62% male, 63% < 75 years old). Overall, among patients aged 35-74 years there were 396 deaths (13%) at 30 days and 585 (19%) at one year; mortality was higher in women (1.28-fold at 30 days, p = 0.02) and in subjects aged 75 years or more (3.26-fold at 30 days, p < 0.0001). There was a progressive reduction in 30 day mortality of 9%/year over the five year period (95% confidence interval, 4% to 13%, p = 0.012). The proportion of one year survivors (35-74 years) in whom serum lipids were measured at least once increased from 74% in 1995 to 88% in 1999; of these, 27% of men and 23% of women had a total serum cholesterol of < 5 mmol/l in 1995, increasing to 65% and 74%, respectively, in 1998 and 1999 (p < 0.0001).
CONCLUSIONS: In the five year period 1995-1999, there was a significant year on year decline in 30 day and one year mortality after admission for acute myocardial infarction, and progressively more patients achieved cholesterol levels below 5 mmol/l. Men were more likely than women to have their lipids measured after myocardial infarction. Mortality at one year was 1.32-fold higher among women than among men.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11997410      PMCID: PMC1767095          DOI: 10.1136/heart.87.5.428

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  15 in total

1.  Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

Authors:  T R Pedersen; A G Olsson; O Faergeman; J Kjekshus; H Wedel; K Berg; L Wilhelmsen; T Haghfelt; G Thorgeirsson; K Pyörälä; T Miettinen; B Christophersen; J A Tobert; T A Musliner; T J Cook
Journal:  Circulation       Date:  1998-04-21       Impact factor: 29.690

2.  Women with angina pectoris receive less antiplatelet treatment than men.

Authors:  M L Bouvy; E R Heerdink; O H Klungel; A de Boer; A G Stuurman-Bieze; H G Leufkens
Journal:  Br J Gen Pract       Date:  1999-04       Impact factor: 5.386

3.  Comparing AMI mortality among hospitals in patients 65 years of age and older: evaluating methods of risk adjustment.

Authors:  H M Krumholz; J Chen; Y Wang; M J Radford; Y T Chen; T A Marciniak
Journal:  Circulation       Date:  1999-06-15       Impact factor: 29.690

4.  A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).

Authors:  T J Bowker; T C Clayton; J Ingham; N R McLennan; H L Hobson; S D Pyke; B Schofield; D A Wood
Journal:  Heart       Date:  1996-04       Impact factor: 5.994

5.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

6.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

7.  Sex differences in myocardial infarction and coronary deaths in the Scottish MONICA population of Glasgow 1985 to 1991. Presentation, diagnosis, treatment, and 28-day case fatality of 3991 events in men and 1551 events in women.

Authors:  H Tunstall-Pedoe; C Morrison; M Woodward; B Fitzpatrick; G Watt
Journal:  Circulation       Date:  1996-06-01       Impact factor: 29.690

8.  Access to coronary catheterisation: fair shares for all?

Authors:  F Kee; B Gaffney; S Currie; D O'Reilly
Journal:  BMJ       Date:  1993-11-20

9.  Recent trends in acute coronary heart disease--mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators.

Authors:  P G McGovern; J S Pankow; E Shahar; K M Doliszny; A R Folsom; H Blackburn; R V Luepker
Journal:  N Engl J Med       Date:  1996-04-04       Impact factor: 91.245

10.  Coronary event and case fatality rates in an English population: results of the Oxford myocardial infarction incidence study. The Oxford Myocardial Infarction Incidence Study Group.

Authors:  J A Volmink; J N Newton; N R Hicks; P Sleight; G H Fowler; H A Neil
Journal:  Heart       Date:  1998-07       Impact factor: 5.994

View more
  1 in total

Review 1.  Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.

Authors:  Jayne E Edwards; R Andrew Moore
Journal:  BMC Fam Pract       Date:  2003-12-01       Impact factor: 2.497

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.